云鼎国际官网

Born in June 1988, Li Jiahong earned a bachelor's degree in business management from the Fresenius University of Applied Sciences in Germany in 2016. In 2012, he worked at Ford Industries Import and Export GmbH. In February 2016, he joined Dongbao Enterprise Group, where he served successively as Secretary to the Chairman, Assistant to the Chairman, and Deputy General Manager of the Group. Since March 2019, he has served as the Group's Chairman and General Manager. He is currently the Chairman of the Company.

Born in September 1974, Leng Chunsheng is a member of the Communist Party of China and a professorate senior engineer. He graduated from Jilin Institute of Chemical Technology in 1997 with a bachelor's degree in fine chemical engineering and earned a doctoral degree in cell biology from Liaoning Normal University in 2013. He joined the Company in 1997 and has been engaged in the research, development, and commercialization of protein-based biologics drugs. He received the second prize of the National Science and Technology Progress Award, and is a recipient of the special allowance granted by the State Council. He is also recognized as a national model worker, a national outstanding science and technology worker, a senior management expert of Jilin Province, and a Changbai Mountain scholar and skill teacher. He currently serves as the Company's Vice Chairman and General Manager.

Born in 1976, Mr. Zhang earned his bachelor's degree in clinical medicine from Tongji Medical University in 1999 and graduated from Renmin University of China in 2011 with a bachelor's degree in business administration. He worked as a Pharmaceutical Sales Representative of Federal Pharmaceuticals Beijing office from 2000-2002, a Medical Specialist of Eli Lilly and Company from 2002-2005, and served as Regional Manager and Deputy General Manager after joining the company in 2005. Mr. Zhang is now a Director and a Deputy General Manager (Sales) of the company.

Born in 1974, Mr. Zhang graduated from Harbin University of Commerce in July 1998 with a bachelor's degree in traditional Chinese pharmacy. He worked as a TCM Pharmacist at Beijing Daxing District Hospital of Traditional Chinese Medicine from July 1998 to February 2002, and a Pharmaceutical Sales Representative of Eli Lilly Asia Inc (Beijing office) from February 2002 to March 2004. He joined the company in 2004, and served as a Regional Manager and a Deputy General Manager. Mr. Zhang is now a Director and a Deputy General Manager (Sales) of the company.

Born in 1983, Mr. Wang graduated from Shanghai Jiao Tong University with a bachelor's degree, and has been a Managing Director of DCP Investments since 2017. He served as an Executive Director at Kohlberg Kravis Roberts & Co. L.P. (Greater China) from 2011 to 2016 and received the KKR Founder's Special Award in 2014 for his valuable contributions to KKR Asia. He served as a Senior Investment Manager at Orchid Asia Group from 2007 to 2011, and a Business Analysis Consultant at McKinsey & Company from 2005 to 2007. Mr. Wang has been dedicated to investment business in healthcare and consumer goods industries for more than ten years, with total investment reaching over USD 1 billion. He initiated and led the investment transactions in Tonghua Dongbao, American-Sino Healthcare Shanghai, Venus MedTech Hangzhou Inc (2500.HK), Qingdao Haier (600690.SH), China Cord Blood Corporation (NYSE:CO), Sinopharm Holding (China) Finance Leasing, Joy Healthcare, Ascendum Capital, Broncus, China Outfitters Holdings (1146.HK), Sino-Ocean Group Holdings (3377.HK), etc. He is now a Supervisor at Venus MedTech Hangzhou Inc, a Director at China Outfitters Holdings, a Director at Sinopharm Holding (China) Finance Leasing, and a member of the Hong Kong Independent Non-Executive Director Association (HKiNEDA). He is also a Director of the company.

Born in December 1990, Zeng Jianchun graduated from the University of Notre Dame in the United States in 2013 with a bachelor's degree in property and economics and from the London School of Economics and Political Science in the United Kingdom in 2014 with a master's degree in finance. In 2014, he served as a project manager at Kearney, a global management consulting firm. Since 2018, he has been with DCP Capital, where he serves as the Director of Post-Investment Management. He has over a decade of experience in management consulting, investment, and post-investment management across multiple industries, including healthcare, industrial manufacturing, and fast-moving consumer goods, and has participated in projects involving operational transformation, corporate governance structure and process optimization, and strategic planning for several Fortune Global 500 companies.

Born in 1966, Ms. Bi is a Senior Accountant, and a Certified Public Accountant. She graduated from the Faculty of Accounting of Jilin Finance and Trade College (now Jilin University of Finance and Economics) in 1989 with a bachelor's degree in economics, and serves as Chief Accountant of Jilin Xinyuan Accounting Firm. Ms. Bi is also an Independent Director of the company.

Born in 1967, Xu Dai is a member of the Communist Party of China and a Doctor of Law. He is a professor and doctoral advisor at the School of Law of Jilin University, and a visiting scholar at Duke University in the United States and at the Faculty of Law, the University of Hong Kong. Prof. Xu is also a member of the National JM Education Steering Committee, the executive director of the Chinese Association of Criminal Law, the vice president of the Chinese Society of Criminology, a member of the Chinese Branch of the International Association of Penal Law, the vice president for criminal law research of Jilin Law Society, the executive vice president and secretary general for crime prevention research of Jilin Law Society, and a member of the Judges and Prosecutors Selection Committee of Jilin Province. He won the 2nd Award for "Top Ten Outstanding Young and Middle-aged Jurists in Jilin Province", and was among the sixteenth batch of experts with allowances granted by the Jilin Provincial Government. His research interests focus on cross-cutting studies of civil and criminal laws and corporate compliance. He has published many papers including one titled "The Dilemma and Solution Concerning the Implementation of Criminal Responsibility Associated with Organizational Crimes." With these papers, he has won the third prize of the Outstanding Achievement Award granted by the China Law Society, and the first prize of the Outstanding Achievement Award for Social Sciences of Jilin Province (twice). Now, he serves as an independent director of Tonghua Dongbao.

Born in 1967, with a Ph.D. in Physical Chemistry, Xu Li is a professor at the School of Life Sciences of Jilin University, a senior research scholar at Arizona State University and George Washington University in the United States, and a visiting professor at Kansai Gakuin University in Japan, and a visiting scholar at INRA Institute in France. His research interests focus on molecular enzymology and targeted drug delivery. He has undertaken many research projects, including one project under the National High-tech R&D Program (863 Program), four projects funded by the National Natural Science Foundation of China, one project supported by the National Administration of Traditional Chinese Medicine, and multiple major projects supported by Jilin Provincial Department of Science and Technology. He has published more than 60 articles in famous journals such as Biosensors & Bioelectronics, ACS Applied Materials & Interfaces, and the Journal of the American Chemical Society. He has won four second prizes of the Natural Science Award of Jilin Province and has been issued four patents. Now, he serves as an independent director of Tonghua Dongbao.